Journals / Yeni Üroloji Dergisi / 2013 / Cilt: 8 - Sayı: 3

Efficacy of percent free PSA and PSA density in the prediction of prostate cancer

Serbest/total PSA oranı ve PSA dansitesinin prostat kanserini öngörmedeki etkinlikleri

Pages
47–53
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: In the prediction of prostate cancer, using percent free PSA and PSAD in combination is more efficient than using these parameters alone.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: We aimed to evaluate predictive abilities of percent free prostate specific antigen PSA and PSA density PSAD in the diagnosis of prostate cancer, alone and in combination.
📊
Key Findings & Data:Materials and Methods: 439 patients who had trans-rectal ultrasound guided prostate biopsy and with a PSA value between 2.5 and 10 ng/ml, normal digital rectal examination findings, and without any history of an intervention, active infection or drug use that would affect PSA levels were included in our study.
💡
Conclusion & Impact:Conclusion: In the prediction of prostate cancer, using percent free PSA and PSAD in combination is more efficient than using these parameters alone.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Prostat kanseri · PSA dansitesi · s/t PSA oranı

Abstract

Objective: We aimed to evaluate predictive abilities of percent free prostate specific antigen PSA and PSA density PSAD in the diagnosis of prostate cancer, alone and in combination. Materials and Methods: 439 patients who had trans-rectal ultrasound guided prostate biopsy and with a PSA value between 2.5 and 10 ng/ml, normal digital rectal examination findings, and without any history of an intervention, active infection or drug use that would affect PSA levels were included in our study. All patients’ pre-biopsy total PSA tPSA , free PSA fPSA , age, prostate volume and biopsy pathology reports were reviewed. We obtained percent free PSA by dividing fPSA to tPSA and obtained PSAD by dividing tPSA to prostate volume. The cut-off value for percent free PSA was 20% and 15% for PSAD. According to pathology results, the patients were divided into two groups as BPH and prostat cancer. Results: The mean age, tPSA, fPSA, prostate volume, percent free PSA, PSAD values of the patients were; 64 ± 8.4 year, 6.3 ± 1.93 ng/ml, 1.28 ± 0.77 ng/ml, 56.5 ± 25.9 ml, 20.2% ± 9.7 and 13.6% ± 7.5, respectively. Between the two groups, fPSA p=0.002 , prostate volume p=0.000 , percent free PSA p=0.002 and PSAD p=0.001 were significantly different while age p=0.311 and tPSA p=0.691 were not. Sensitivity of percent free PSA was 73%, specificity 45%, positive predictive value PPV 21%, negative predictive value NPV 89% and accuracy 50%. Sensitivity of PSAD was 57%, specificity 74%, PPV 31%, NPV 89% and accuracy 71%. Sensitivity of using both parameters in combination was 50%, specificity 79%, PPV 33%, NPV 88% and accuracy 74%. Conclusion: In the prediction of prostate cancer, using percent free PSA and PSAD in combination is more efficient than using these parameters alone.

Özet

Giriş: Serbest/total s/t prostat spesifik antijen PSA oranı ve PSA dansitesinin PSAD tek tek ve kombine olarak prostat kanserini öngörmedeki etkinliklerinin araştırılması. Gereç ve Yöntemler: Çalışmamıza PSA değeri 2.5-10 ng/ml iken transrektal ultrasonografi eşliğinde prostat biyopsisi alınan, parmakla rektal muayene bulguları normal ve PSA düzeyini etkileyecek herhangi bir girişim, aktif enfeksiyon veya ilaç kullanım öyküsü olmayan 439 hasta dahil edildi. Tüm hastaların biyopsi öncesi total PSA, serbest PSA, yaş, prostat hacmi değerleri ve biyopsi sonrası patoloji raporları tarandı. Serbest PSA’nın sPSA total PSA’ya tPSA bölünmesiyle s/t PSA oranı ve tPSA’nın prostat hacmine bölünmesiyle PSAD elde edildi. Sınır değerler s/t PSA oranı için %20, PSAD için %15 olarak alındı. Hastalar patoloji sonucuna göre BPH ve prostat kanseri olarak iki gruba ayrıldı. Bulgular: Hastaların ortalama yaş, tPSA, sPSA, prostat hacmi, s/t PSA oranı, PSAD değerleri sırasıyla 64 ± 8.4 yıl, 6.3 ± 1.93 ng/ml, 1.28 ± 0.77 ng/ml, 56.5 ± 25.9 ml, % 20.2 ± 9.7 ve % 13.6 ± 7.5’ti. Gruplar arasında yaş p=0.311 ve tPSA p=0.691 açısından fark saptanmazken, sPSA p=0.002 , prostat hacmi p=0.001 , s/t PSA oranı p=0.002 ve PSAD p=0.001 anlamlı derecede farklı olarak bulundu. s/t PSA oranının duyarlılığı %73, özgüllüğü %45, pozitif öngörü değeri PÖD %21, negatif öngörü değeri NÖD %89 ve doğruluğu %50 olarak bulundu. PSAD’nin ise duyarlılığı %57, özgüllüğü %74, PÖD %31, NÖD %89 ve doğruluğu %71 olarak bulundu. Bu iki PSA parametresi kombine kullanıldığında duyarlılık %50, özgüllük %79, PÖD %33, NÖD %88 ve doğruluk %74 olarak saptandı. Sonuç: s/t PSA oranı ve PSAD’nin kombine olarak kullanımı, prostat kanserini öngörmede bu parametrelerin tek tek kullanımlarından daha etkilidir

🔖

Cite This Article

KAĞAN, B. A., BULUT, S., KESKİN, M. Z., GÖKKAYA, C. S., ÖZDEN, C., BAYKAM, M. M., MEMİŞ, A. (2013). Efficacy of percent free PSA and PSA density in the prediction of prostate cancer. Yeni Üroloji Dergisi, Cilt: 8 - Sayı: 3, 47–53. https://ajindex.com/articles/337282

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Boyle P, Ferlay J. Cancer incidence and mortality in Europe 2004. Ann Oncol 2005;16:481-8.
  2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
  3. Eser S, Yakut C, Özdemir R, et al. Cancer incidence rates in Turkey in 2006: a detailed registry based estimation. Asian Pac J Cancer Prev 2010;11:1731-9.
  4. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ confined prostate cancer is increased through prosta- te spesific antigen based screening. JAMA 1993;270:948-54.
  5. Günay LM, Yazıcı S, Özen H. PSA nereden geldi nereye gi- diyor? Üroonkoloji Bülteni 2011;2:5-10.
  6. Polascik TJ, Oesterling JE, Partin AW. Prostate specific anti- gen: a decade of discovery--what we have learned and whe- re we are going. J Urol 1999;162:293-306.
  7. Catalona WJ, Southwick PC, Slawin KM, et al. Compari- son of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology 2000;56:255-60.
  8. Seaman E, Whang M, Olsson CA, et al. PSA density (PSAD). Role in patient evaluation and management. Urol Clin North Am 1993;20:653-63.
  9. Luderer AA, Chen YT, Soriano TF, et al. Measurement of the proportion of free to total prostate-specific antigen imp- roves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology 1995;46:187-94.
  10. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324:1156-61.
  11. Brawer MK, Chetner MP, Beatie J, et al. Screening for prostatic carcinoma with prostate specific antigen. J Urol 1992;147:841-5.
  12. Morote J, Trilla E, Esquena S, et al. The percentage of free prostatic-specific antigen is also useful in men with normal digital rectal examination and serum prostatic-specific an- tigen between 10.1 and 20 ng/ml. Eur Urol 2002;42:333-7.
  13. Stenman UH, Leinonen J, Alfthan H, et al. A complex bet- ween prostate-specific antigen and alpha 1-antichymotry- psin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex imp- roves clinical sensitivity for cancer. Cancer Res 1991;51:222- 6. Woodrum DL, Brawer MK, Partin AW, Catalona WJ, So- uthwick PC. Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J Urol 1998;159:5-12.
  14. Catalona WJ, Partin AW, Slawin KM, et al. Use of the per- centage of free prostate-specific antigen to enh